 Kintara Therapeutics Inc NASDAQ:KTRA, which is focused on the development of new solid tumor cancer therapies, said it closed its fiscal third quarter with cash and cash equivalents of about 15.7 million. That capital, the company said, is expected to be sufficient to fund its planned operations to the second quarter of calendar year 2022. 